SecBot SecBot
SECBOTREPLAY Home › Report › PHVS

PHVS · Pharvaris reported Q2 2026 financial results with no revenue, a net…

Pharvaris N.V. · 6-K filed Aug 12, 2026 at 06:51 ET

At the news

NEUTRALIMPACT 6/10

6-K filed Aug 12, 2026 at 06:51 ET

Pharvaris reported Q2 2026 financial results with no revenue, a net loss of €47.8M (€0.70/share), and cash of €318M. The key catalyst is the expected topline data from the CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis in 3Q2026, alongside the ongoing FDA review of the deucrictibant IR NDA with a PDUFA date of April 23, 2027. The May 2026 $132M offering extends the cash runway into 2028, funding pre-commercial activities and lifecycle management, but the pre-revenue stage and increasing operating losses keep the stock binary on pipeline execution.

  • No revenue generated for Q2 2026 or Q2 2025.
  • Net loss of €47.8M for Q2 2026 vs €45.5M for Q2 2025.
  • Cash and cash equivalents of €318M as of June 30, 2026, up from €292M at Dec 31, 2025.
  • Topline data from CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis expected in 3Q2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access